Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi: Information concerning the total number of voting rights and shares - December 2025
12:30pm, Wednesday, 14'th Jan 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
10:20am, Tuesday, 13'th Jan 2026
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
07:38am, Tuesday, 13'th Jan 2026
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
05:34pm, Monday, 12'th Jan 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:26pm, Monday, 12'th Jan 2026
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
01:00am, Monday, 12'th Jan 2026
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
08:30am, Wednesday, 07'th Jan 2026
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.
Allspring Global Investments Holdings LLC Sells 10,390 Shares of Sanofi $SNY
03:18am, Wednesday, 07'th Jan 2026
Allspring Global Investments Holdings LLC reduced its stake in shares of Sanofi (NASDAQ: SNY) by 7.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
07:30am, Tuesday, 06'th Jan 2026
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announce
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
11:26am, Monday, 05'th Jan 2026
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
01:40am, Monday, 05'th Jan 2026
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
01:00am, Monday, 05'th Jan 2026
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Traders Buy High Volume of Sanofi Put Options (NASDAQ:SNY)
01:51am, Tuesday, 30'th Dec 2025
Sanofi (NASDAQ: SNY - Get Free Report) saw some unusual options trading activity on Monday. Stock traders acquired 14,850 put options on the company. This is an increase of approximately 370% compared
